High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: Long-term outcome and prognostic factors

Annals of Hematology

Volumn 79, Issue 10, 2000, Pages 547-555

  Neben, K ^a   Hohaus, S ^a   Goldschmidt, H ^a   Egerer, G ^a   Voso, M T ^b   Ho, A D ^a   Haas, R ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Autologous transplantation; Hodgkin's disease; Mobilization; Peripheral blood stem cell transplantation; Prognostic factors

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INFECTIOUS COMPLICATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033783428     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770000190     Document Type: Article

References (35)

1. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents
2. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
3. Autologous transplantation with peripheral blood mononuclear ceils collected after administration of recombinant human granulocyte colony-stimulating factor
4. The place of high-dose therapy with autologous stem cell transplantation in primary treatment of Hodgkin's disease
5. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease
6. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients
7. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation
8. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma
9. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
10. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
11. Detection and significance of pulmonary Hodgkin's disease at autologous bone marrow transplantation
12. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor
13. Recombinant human granulocyte colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem ceils for autografting in patients not eligible for bone marrow harvest
14. Patient characteristics associated with successful mobilization and autografting of blood progenitor cells in malignant lymphoma
15. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support
16. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF
17. Recombinant human granulocyte and granulocyte-macrophage colony stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells
18. Primary refractory Hodgkin's disease
19. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
20. High dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease
21. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation
22. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: A phase I/II study
23. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site
24. Autotransplantation for relapsed or refractory Hodgkin's disease: Long-term follow-up and analysis of prognostic factors
25. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry
26. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors
27. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's disease study group
28. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
29. Ideopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease
30. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
31. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma
32. Carmustine and the lungs
33. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1)
34. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants
35. Comparison between conventional salvage therapy with autografting for recurrent or refractory Hodgkin's disease